Clinical and microbiological characteristics of bloodstream infections in hematological cancer patients

Cover Page

Cite item

Full Text

Abstract

Introduction. Bloodstream infections (BSI) are life-threatening illness for immunocompromised patients with hematological malignancies.
The aim of the study was to compare epidemiology, causative pathogens and outcome of hospital-acquired BSI and clarifying the role of herpes group of viruses in their development.
Materials and methods. During the period 1991–2013 438 bacterial strains obtained from 360 patients (pts) with hematological malignancies wеre studied. All blood cultures were incubated in the continuous monitoring system for 7 days before discard. The real-time PCR was used for human herpesviruses DNA detection: Herpes simplex viruses types 1 and 2 (HSV 1, 2), Cytomegalovirus (CMV), Epstein–Barr virus
(EBV) and Herpesvirus 6 (HHV-6). In this study 64 hematological cancer patients with infectious complications who fulfilled criteria of systemic inflammatory response syndrome with positive peripheral blood cultures were investigated. All pts received empirical anti-infectious therapy with subsequent correction based on the bacteriological, virological and mycological analyses.
Results and discussion. A total Gram-positive (G+) accounted for 69.2 % of BSI, Gram-negative (G–) for 30.8 %. Among G+ BSI Coagulase Negative Staphylococci and Staphylococcus aureus were the most frequent pathogens (58.8 %), among G– BSI Escherichia coli (13.0 %) was predominant. It is shown that the development of bacteremia were significantly more frequently occurs in the case of cytomegalovirus
and the Epstein–Barr virus detection.
Conclusion. Further epidemiological surveillance is warranted in order emerging resistant strains and related mortality. Reactivation of CMV and EBV is significantly associated with higher incidence of bacterial BSI.

About the authors

V. N. Chebotkevich

Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency

Author for correspondence.
Email: vitnikcheb@mail.ru
Russian Federation

S. S. Bessmel’tsev

Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency

Russian Federation

E. E. Kiseleva

Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency

Russian Federation

N. P. Stizhak

Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency

Russian Federation

E. I. Kaytandzhan

Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency

Russian Federation

V. V. Burylev

Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.